ghk-cu injection site pain Mitigating Pain: Tips and Tricks | Gabriel Alizaidy, MD, MS posted on the topic GHK-Cu Peptide Therapy: The Definitive

Most treatments target one mechanism

References to clinical trials, body-weight outcomes, glucose-related measures, or other human endpoints are not claims about this product and do not indicate that it is intended for human or animal use

Early studies suggest antioxidant properties and matrix turnover mechanisms that may be relevant in acute injuries and chronic overuse conditions

To the extent possible, alternate plans will be needed and the challenges will be substantial

WADA Prohibition The World Anti-Doping Agency classifies both peptides as prohibited substances: Both listed under Section S0 (Non-Approved Substances) Prohibited at all times (in and out of competition) No Therapeutic Use Exemptions (TUEs) available for either peptide Detection methods under development for anti-doping testing TB-500 and thymosin beta-4 explicitly banned since 2011 WADAs position reflects that neither peptide has regulatory approval from any health authority worldwide